The Analyst Verdict: Crinetics Pharmaceuticals In The Eyes Of 6 Experts
Portfolio Pulse from Benzinga Insights
Crinetics Pharmaceuticals (NASDAQ:CRNX) has been evaluated by 6 analysts over the past three months, showing a mix of bullish and bearish sentiments. The average 12-month price target is $49.00, indicating an 8.89% increase from the previous target of $45.00. Analysts' actions range from 'Maintain' to 'Raise', with ratings from 'Outperform' to 'Buy'. The company's financials reveal challenges, including a -24.45% revenue decline and a net margin of -16606.36%, indicating potential profitability and cost management issues.
February 29, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Crinetics Pharmaceuticals has received mixed analyst ratings with a new average price target of $49.00. Financial challenges include a significant revenue decline and a net margin of -16606.36%.
The mixed analyst ratings with a new higher price target suggest a cautiously optimistic outlook for CRNX. However, the significant financial challenges highlighted, such as the revenue decline and poor net margin, could temper investor enthusiasm. The positive price target adjustment indicates a belief in potential upside, but the financial health concerns may limit short-term gains.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100